Unigene Initiates Phase I/II Clinical Study For Oral Calcitonin
The tablets being tested in the study utilize the same improved solid dosage form of Unigene's Enteripep® oral delivery technology used in Unigene's prior oral calcitonin study that was completed last fall. In that study, the new dosage form achieved a biological response in 100% of the study subjects.
"We are very pleased with the performance to date of these improved tablets," reported Dr. Ronald S. Levy, Executive Vice President of Unigene. "They have performed well in both animal and human studies and have demonstrated all of the properties required for a pharmaceutically-acceptable dosage form, including stability, bioavailability and dosing consistency. We have already shown that they can effectively deliver other peptides in repeated animal testing. The refinements that we have incorporated have clearly enhanced our original formulation technology and at the same time have enabled us to establish an even stronger intellectual property portfolio."
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical® to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, visit http:// www.unigene.com. For information about Fortical, visit http://www.fortical.com.
Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.'s management's current expectations, estimates, beliefs, assumptions, and projections about Unigene's business and industry.
Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene's cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene's Securities and Exchange Commission filings.
Unigene Laboratories, Inc.
Unigene initiaza studii, de fazã I / II, studiu clinic pentru oral Calcitonin - Unigene Initiates Phase I/II Clinical Study For Oral Calcitonin - articole medicale engleza - startsanatate